Trial Profile
A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 08 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 Apr 2019 Primary endpoint has been met. (Change in Smoking Intensity), according to an Axsome Therapeutics media release.
- 15 Apr 2019 According to an Axsome Therapeutics media release, Duke University has completed topline analysis of the trial.